LifeMD to launch self-pay testosterone program with Antares Pharma

LifeMD, Inc. (Nasdaq: LFMD) announced an exclusive co-marketing agreement with Antares Pharma, Inc., a wholly owned subsidiary of Halozyme, to support a direct-to-patient self-pay program for XYOSTED® (testosterone enanthate) injection, an FDA-approved once-weekly subcutaneous testosterone auto-injector.

The program is scheduled to launch in July 2026 and will initially be available in 37 states. Under the arrangement, LifeMD will serve as the exclusive telehealth co-marketing partner, with patient evaluations conducted through LifeMD's affiliated medical group and XYOSTED dispensed through LifeMD's pharmacy and shipped directly to patients' homes.

The self-pay program is priced at approximately $249 per month, covering both medication and clinical care with no insurance required. Services included in that price are virtual consultation, lab-based diagnosis, ongoing clinical support, dose management, and refill support. The companies said they plan to expand the program to insurance-based patients and additional states as telehealth prescribing regulations allow.

XYOSTED was approved by the FDA in 2018 for testosterone replacement therapy in adult males with conditions associated with a deficiency or absence of endogenous testosterone. The drug is classified as a Schedule III controlled substance.

"Millions of men suffer from low testosterone and never receive guideline-based care because the path to treatment is too fragmented and too expensive," said Justin Schreiber, Chairman and Chief Executive Officer of LifeMD.

"XYOSTED is a proven therapy. Our collaboration with LifeMD is about making sure the right patients can actually access it," said Dr. Helen Torley, President and Chief Executive Officer of Halozyme.

According to the press release, 99.4% of injections were reported to be pain-free in a one-year clinical trial of 150 patients, though injection site reactions were reported in 12.7% of participants. No patients discontinued the drug due to injection site reactions.

You May Also Be Interested In

• Chevron signed an agreement with Iraq's Basra Oil Company to advance commercial negotiations for West Qurna 2
• Hilton Grand Vacations refinances $850M term loan, extends to 2033
• Richard Lowenthal resigns from ARS Pharmaceuticals board